Kyowa Kirin, Inc. respects your interest in keeping your personal and professional information private. We will not sell or rent your information to any third parties or outside mailing lists.
SANCUSO® (granisetron transdermal system) is indicated for the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration.
SANCUSO is contraindicated in patients with known hypersensitivity to granisetron or to any of the components of the patch.
Warnings and Precautions
The most common adverse reaction in patients receiving SANCUSO is constipation (5.4%).